ArticleFrontiers in oncology2025
Diagnostic accuracy of PSA derivatives for prostate cancer in patients with low prostate-specific antigen levels.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Magnetic Resonance Imaging-Based Artificial Intelligence in Predicting Prostate Cancer Biochemical Recurrence: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- Dual-center development and external validation of machine learning models integrating PSA-derived and peripheral inflammatory markers for prostate cancer diagnosis.Translational andrology and urology · 2026Article
- Additional predictive value of systemic inflammation indices beyond prostate specific antigen density for clinically significant prostate cancer.BMC urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific antigen (PSA) has long been used to screen for prostate cancer (PCa), yet its low diagnostic sensitivity in the so-called PSA "gray zone" often results in overdiagnosis or missed diagnoses. This study aimed to identify reliable diagnostic markers for PCa in patients with serum PSA levels ≤10 ng/mL by comparing various PSA derivatives. Clinical data from 60 patients (PSA ≤10 ng/mL) treated between 2013 and 2023 were retrospectively analyzed. Prostate volume was measured via suprapubic ultrasonography. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic performance of total PSA (tPSA), free PSA (fPSA), the free-to-total PSA ratio (f/tPSA), PSA density (PSAD), and the PSA-age volume index (PSA-AV). Area under the curve (AUC) values for tPSA, fPSA, f/tPSA, PSAD, and PSA-AV were 0.8301, 0.6830, 0.7225, 0.9318, and 0.9103, respectively. fPSA demonstrated the lowest diagnostic accuracy. tPSA showed moderate performance. Both PSAD and PSA-AV outperformed tPSA and f/tPSA, with positive predictive values of 89.47% and 74.07% and negative predictive values of 87.80% and 93.94%, respectively. PSAD demonstrated higher specificity (94.74%), while PSA-AV showed higher sensitivity (90.91%). PSAD appears to be a superior noninvasive diagnostic marker, while PSA-AV holds promise as an effective screening tool in patients with PSA ≤10 ng/mL. Given the small sample size, these findings should be regarded as preliminary and hypothesis-generating, pending validation in larger multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.